HepVu Logo


Launched in partnership with Emory University, HepVu.org provides users with visualized data, interactive maps, and educational resources that illustrate the hepatitis C (HCV) epidemic in the United States. Gilead is proud of our ongoing partnership with and commitment to HepVu’s mission of making data widely available, easily accessible and locally relevant to inform public health decision-making.

HepConnect Logo


HepConnect is a five-year, multimillion-dollar initiative aimed at addressing the increase in HCV infections. In partnership with local organizations, the initiative will develop and implement evidence-based solutions to meet the needs of people most affected by the opioid crisis.

Picture of Globe

Race to Elimination

This report, published by the Boston Consulting Group in collaboration with expert advisers and key opinion leaders, assesses how European countries are progressing towards the elimination goal, recognizing policy barriers along with recommended priority policy actions that countries can take to achieve the elimination goal. It also reviews key population groups affected by HCV and shares effective, validated models of care built around the needs of these groups. The aim is to support policymakers identify international models of best practices to support elimination efforts in their own countries.

Download the BCG report
Download the factsheet

Value of Cure Infographic

This infographic sets out the real-world clinical and financial benefits that countries are starting to see from HCV cure, including reduction in HCV mortality, reduction in liver transplants due to HCV and reduction in HCV morbidity – along with associated cost savings. These real-world results demonstrate that an up-front investment in elimination programmes can yield short- and medium-term savings to health systems. See the infographic here.

HCV Elimination Factsheet

Gilead is committed to achieving the World Health Organization's targets of Hepatitis C elimination by 2030. This factsheet details the global status of progress towards elimination, including outlining some of the inequalities in HCV care and the steps Gilead is taking to reach the goal of HCV elimination by 2030. Read the factsheet here.

Mobile Hepatitis Team, France


TraP Hep C, Iceland

Project Arkhangai, Mongolia

COMMIT Grantee Video: EpaC Onlus, Italy

Global Access

Highlighting Gilead’s commitment to ensuring everyone has access to prevention and treatment medications, regardless of where they live or their economic status.

Person with child